Rain Therapeutics Announces a Poster Presentation at the 2022 San Antonio Breast Cancer Symposium

Rhea-AI Summary

Rain Therapeutics Inc. (NasdaqGS: RAIN) has announced a poster presentation at the 2022 San Antonio Breast Cancer Symposium, scheduled for December 6-10, 2022. The presentation will focus on genetic alterations in breast cancer linked to MDM2 dependency and sensitivity to milademetan, an oral inhibitor targeting the MDM2-p53 complex. The poster session is set for December 9, 2022, at the Henry B. Gonzalez Convention Center. Rain aims to use precision oncology to select patients based on genetic profiles rather than tumor histology.

Positive

• Scheduled presentation at a prominent industry symposium could enhance visibility and credibility.
• Focus on precision oncology may attract investor interest due to the growing importance of personalized medicine.

Negative

• Presentation may not lead to immediate commercialization or revenue generation.
• Potential risks associated with clinical trial outcomes and the effectiveness of milademetan remain.

NEWARK, Calif., Nov. 23, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (Rain), a late-stage biotechnology company developing precision oncology therapeutics with a lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, today announced a poster presentation at the upcoming 2022 San Antonio Breast Cancer Symposium (SABCS) taking place on December 6-10, 2022 in San Antonio, TX.

Presentation Title:	Genetic alterations in breast cancer associated with MDM2 dependency and sensitivity to the MDM2 inhibitor milademetan
Authors:	Francois-Clement Bidard, Diana Bello Roufai, Arielle J. Medford, Vijaya Tirunagaru, Robert C. Doebele, Aditya Bardia
Poster Session / Category:	Session 6 / Treatment: Therapeutic Strategies – Novel Targets and Targeted Agents
Poster Number:	P6-10-10
Session Date and Time:	Friday, December 9, 2022; 7:00 AM CT
Location:	Henry B. Gonzalez Convention Center, Hall 1

A copy of the presentation materials can be accessed by visiting the "Resources” section of the Rain website after the conclusion of the presentation and will be archived on the Rain website.

About Rain Therapeutics Inc.
Rain Therapeutics Inc. is a late-stage precision oncology company developing therapies that target oncogenic drivers to genetically select patients it believes will most likely benefit. This approach includes using a tumor-agnostic strategy to select patients based on their tumors’ underlying genetics rather than histology. Rain’s lead product candidate, milademetan, is a small molecule, oral inhibitor of MDM2-p53 complex that reactivates p53. In addition to milademetan, Rain is also developing a preclinical program that is focused on inducing synthetic lethality in cancer cells by inhibiting RAD52.

Investor Contact
Dan Ferry
LifeSci Advisors
+1.617.430.7576
daniel@lifesciadvisors.com

Media Contact
Jordyn Temperato
LifeSci Communications
jtemperato@lifescicomms.com

FAQ

What is Rain Therapeutics presenting at the San Antonio Breast Cancer Symposium?

Rain Therapeutics will present on genetic alterations in breast cancer related to MDM2 dependency and sensitivity to milademetan.

When is Rain's poster session at the SABCS?

The poster session is scheduled for December 9, 2022, at 7:00 AM CT.

Where will the Rain Therapeutics presentation take place?

The presentation will be held at the Henry B. Gonzalez Convention Center in San Antonio, TX.

What is milademetan?

Milademetan is an oral small molecule inhibitor of the MDM2-p53 complex that is being developed by Rain Therapeutics.

What is the significance of the MDM2-p53 complex in cancer therapy?

The MDM2-p53 complex is critical in cancer biology, and targeting it may help reactivate p53, a key tumor suppressor.